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Abstract
Background: Within the context of increasing antimalarial costs and or decreasing malaria transmission, the
importance of limiting antimalarial treatment to only those confirmed as having malaria parasites becomes
paramount. This motivates for this assessment of the cost-effectiveness of routine use of rapid diagnostic tests
(RDTs) as an integral part of deploying artemisinin-based combination therapies (ACTs).
Methods: The costs and cost-effectiveness of using RDTs to limit the use of ACTs to those who actually have
Plasmodium falciparum parasitaemia in two districts in southern Mozambique were assessed. To evaluate the
potential impact of introducing definitive diagnosis using RDTs (costing $0.95), five scenarios were considered,
assuming that the use of definitive diagnosis would find that between 25% and 75% of the clinically diagnosed
malaria patients are confirmed to be parasitaemic. The base analysis compared two ACTs, artesunate plus
sulfadoxine/pyrimethamine (AS+SP) costing $1.77 per adult treatment and artemether-lumefantrine (AL) costing
$2.40 per adult treatment, as well as the option of restricting RDT use to only those older than six years.
Sensitivity analyses considered lower cost ACTs and RDTs and different population age distributions.
Results: Compared to treating patients on the basis of clinical diagnosis, the use of RDTs in all clinically diagnosed
malaria cases results in cost savings only when 29% and 52% or less of all suspected malaria cases test positive for
malaria and are treated with AS+SP and AL, respectively. These cut-off points increase to 41.5% (for AS+SP) and
to 74% (for AL) when the use of RDTs is restricted to only those older than six years of age. When 25% of
clinically diagnosed patients are RDT positive and treated using AL, there are cost savings per malaria positive
patient treated of up to $2.12. When more than 29% of clinically diagnosed cases are malaria test positive, the
incremental cost per malaria positive patient treated is less than US$ 1. When relatively less expensive ACTs are
introduced (e.g. current WHO preferential price for AL of $1.44 per adult treatment), the RDT price to the
healthcare provider should be $0.65 or lower for RDTs to be cost saving in populations with between 30 and
52% of clinically diagnosed malaria cases being malaria test positive.
Conclusion: While the use of RDTs in all suspected cases has been shown to be cost-saving when parasite
prevalence among clinically diagnosed malaria cases is low to moderate, findings show that targeting RDTs at the
group older than six years and treating children less than six years on the basis of clinical diagnosis is even more
cost-saving. In semi-immune populations, young children carry the highest risk of severe malaria and many
healthcare providers would find it harder to deny antimalarials to those who test negative in this age group.
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Malaria is a complex disease that varies in epidemiology
and public health impact in different parts of the world.
Estimates by the World Health Organization indicate that
there are 350–500 million clinical cases of malaria each
year [1]. These figures may be a significant under-estimate
of the true malaria toll considering that the greatest
impact of malaria occurs in areas where surveillance and
reporting systems are weak. However, it is also possible
that these statistics are over-estimated given that the areas
where the greatest proportion of malaria cases occur rely
mostly on clinical diagnosis of malaria, which usually
includes many other acute febrile illnesses. Administra-
tion of antimalarial treatment has been predominantly
based on clinical diagnosis [2-10]. More recently, how-
ever, the availability of rapid diagnostic tests (RDTs) has
led to definitive diagnosis being considered as a strategy
to target the use of antimalarials [3-12].
Clinical diagnosis has the key advantage of being cheap
and easy to perform in rural settings and by those with
limited training. In addition, the diagnosis is made rela-
tively quickly (compared to definitive diagnosis where a
health worker has to perform the test and/or wait for test
results), allowing for quick provision of antimalarial treat-
ment. Clinical diagnosis is, however, likely to result in
erroneous treatment of millions of non-malaria cases.
Misdiagnosis of malaria is costly and results in considera-
ble morbidity and mortality, because it contributes to
both a delay in treatment of the correct diagnosis and to
increasing antimalarial drug pressure and thus resistance,
thereby speeding up the obsolescence of affordable drugs
[4,5].
Definitive diagnosis, when used correctly, can contribute
to better and more cost-effective disease management and
can reduce the unnecessary use of antimalarial drugs.
Although microscopy is considered to be the gold stand-
ard for malaria diagnosis [2-5] and has several advantages
over other diagnostic approaches, it has been found to be
operationally impractical in rural or resource-poor set-
tings due to its requirements for personnel, equipment,
regular supply of reagents and continued quality assur-
ance supervision [2-4]. Rapid diagnostic tests offer the
possibility for accurate and accessible detection of malaria
parasites, and have an important role in limiting malaria
over-diagnosis and over-treatment [9-15], particularly
where accurate microscopy is not accessible. Provided
they do actually reduce the prescription of antimalarials,
RDTs are expected to become more cost-effective as anti-
malarials become increasingly expensive and/or the risk
of malaria is reduced. Extensive resistance to chloroquine,
sulphadoxine-pyrimethamine (SP) and amodiaquine
monotherapy has prompted malaria treatment policy
change to more expensive combinations, especially
artemisinin-based combination therapies (ACTs). Wide-
spread use of artemisinin-based combination therapies
has been shown to decrease malaria transmission in Zan-
zibar [16], South Africa [17] and Thailand [18]. Similarly,
high coverage with effective indoor residual spraying pro-
grammes [19] or insecticide-treated bed nets [20,21] have
resulted in sustained reductions in malaria risk.
The role of definitive diagnosis or rapid diagnostic tests is
more uncertain in areas with high intensity malaria trans-
mission. In these areas, it has been considered acceptable
to treat on a clinical diagnosis on the grounds that a high
proportion of febrile cases are actually parasitaemic and
that it is better to treat all febrile cases than to miss one
potentially fatal malaria infection, especially in young
children [22]. On the other hand, it could also be argued
that there is a greater likelihood for partial immunity in
the adult populations living in areas of high transmission
intensity and, therefore, it is likely that a smaller propor-
tion of their fevers would actually be malaria cases.
Within the context of increasing antimalarial costs and/or
decreasing malaria transmission, the importance of limit-
ing antimalarial treatment to only those confirmed as
having malaria parasites becomes paramount [2,4,9]. This
provides the rationale for the assessment of the cost-effec-
tiveness of routine use of RDTs as an integral part of
deploying artemisinin-based combination therapies, par-
ticularly in context of low to moderate intensity malaria
transmission.
Methods
This study was undertaken in two districts in southern
Mozambique (Namaacha and Matutuine). Both districts
in Mozambique were in holoendemic malaria transmis-
sion areas with Plasmodium falciparum prevalence among
children aged 2–15 years of over 60% prior to the imple-
mentation of a community based indoor residual spray-
ing (IRS) programme [23]. The aim of this study was to
determine whether RDTs should be implemented prior to
the introduction of artesunate plus SP (AS-SP) to replace
chloroquine as first-line malaria treatment and arte-
mether-lumefantrine to replace SP as second-line treat-
ment within the public sector. The costs and cost-
effectiveness of using RDTs to limit the use of ACTs to
those who actually have malaria, under different scenarios
of malaria parasite prevalence (25% – 75%) among clini-
cally suspected malaria cases were assessed. In addition,
the analysis included an evaluation and comparison of
two differently priced ACTs and assessed restricting RDTs
to only those older than six years.
Before the implementation of ACTs and RDTs in the two
pilot districts in southern Mozambique, relevant baseline
data on malaria-related costs and health outcomes werePage 2 of 14
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which comprised of 13 health posts (clinics) and two
health centres (district hospitals). Costing was undertaken
from a public sector provider's perspective and included
the costs of RDTs and antimalarials for malaria outpa-
tients. Capital costs were excluded from this analysis since
RDTs do not require additional equipment or infrastruc-
ture.
The estimation of treatment costs for non-malaria febrile
cases (those who are malaria test negative), some of
whom would be treated for other illnesses, was beyond
the scope of this study and is, therefore, not assessed or
discussed further.
For this study, data on the number and age distribution of
clinically diagnosed malaria cases for the year 2002 were
obtained from the provincial and district Ministry of
Health records in the 15 health facilities studied. Based on
the age distribution observed from this facility data, the
proportions of clinically diagnosed malaria patients in
each age category were calculated for artesunate plus SP
(Table 1). Proportions in the different age categories used
for dosing artemether-lumefantrine were then extrapo-
lated assuming even age distribution within each age cat-
egory (Table 1).
Calculating costs
The calculation of costs is based on the number of sus-
pected malaria cases (for the clinical diagnosis scenario)
and on the calculated malaria cases for each scenario of
definitive diagnosis considered (25% – 75% of suspected
cases being confirmed malaria cases).
Cost of antimalarials
ACT dosages (and thus costs) are dependent on patient
age (or weight) (see Table 1). Children under one year of
age were excluded from this analysis as the Maputo pro-
vincial guidelines recommend that this high-risk group is
admitted to the health centre for treatment with quinine.
The costs of AS+SP and artemether-lumefantrine have
been calculated as unit price in 2004 (see Table 2) multi-
plied by the estimated quantity of antimalarials consumed.
The unit price of artesunate is based on the cost of $0.10
per 50 mg tablet for the only artesunate product pre-
accredited by the WHO at the time of the study
(Arsumax®, Sanofi-Aventis, Paris, France). The price at
which Mozambique ordered SP (Fansidar®, a fixed dose
combination of 500 mg sulphadoxine plus 25 mg
pyrimethamine manufactured by Roche, Johannesburg
South Africa) for the pilot ACT deployment of $0.19 per
tablet, was used in the analyses. The unit prices of arte-
mether-lumefantrine (Coartem® 20 mg artemether and
120 mg lumefantrine, Novartis, Basel, Switzerland) are
based on the WHO preferential price at the time of the
study of $2.40 per adult treatment [24]. Sensitivity analy-
ses included the subsequently reduced WHO preferential
prices of AL of $1.44 per adult treatment. Quantities of
antimalarials consumed were calculated with the assump-
tions that malaria patients would receive the recom-
mended doses of antimalarials and that there was no
wastage of antimalarials.
Cost of RDTs
The cost of RDTs was calculated as the unit price of RDTs
multiplied by the estimated quantity of RDTs used. For pre-
vious surveys in the study area, the Mozambican Ministry
of Health was using RDTs (ICT Diagnostics PF Tests
ML01®) for which a box of 25 RDT tests was obtained at a
price of $23.72. This translates into a unit price of USD
0.95 (2003 prices). Quantity of RDTs used was estimated
assuming that each clinically diagnosed malaria case
would be tested using one RDT.
Costing under the different scenarios
Given the reliance on clinical diagnosis of malaria, actual
malaria incidence in most sub-Saharan countries is not
known. Analyses presented in this paper focus on a wide
range of scenarios reflecting varying levels of malaria
endemicity and consider that between 25% and 75% of
Table 1: Age distribution of patients with clinically diagnosed malaria in Namaacha and Matutuine districts, southern Mozambique (n = 
31,438)
AS+SP artemether-lumefantrine
Age Observed n (percentage) Age Estimated percentage Basis for calculation*
1–6 years 8,882 (28.3%) 1–5 years 23.6% As for AS+SP, less 4.7% to cater for 6 year olds
7–13 years 4,814 (15.3%) 6–8 years 9.1% As for AS+SP, plus 4.7% to include 6 year olds, minus 
10.9% to exclude 9–13 year olds
14+ years 17,742 (56.4%) 9–12 years 8.7% 100% minus the other age categories' %
13+ years 58.6% As for AS+SP, plus 2.2% to include 13 year olds
100% 100%
* assuming even age distribution within each age category.Page 3 of 14
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when an RDT is used. It was assumed that these propor-
tions were constant across all age groups, although in
areas of intense malaria transmission the proportion of
RDT positive patients may be expected to decrease with
age as partial immunity is required. To address this, the
study included an analysis of the costs and cost-effective-
ness of limiting RDT use to patients over six years of age.
The cost-effectiveness of RDTs is largely driven by the cost
of treatment (ACTs) relative to the cost of diagnosis. The
rationale for using the cut-off as six years of age was
because of the age-based dosage for artesunate plus SP,
the ACT planned for deployment in Mozambique,
increasing from one tablet ($0.49) for children aged 1 – 6
years to two tablets ($0.98) for children aged 7 – 13 years.
Since the cost of RDTs ($0.95) remains constant regard-
less of age, the possibility of RDTs being cost saving would
only arise for children over six years of age when artesu-
nate plus SP is treatment policy.
Total cost savings (or incremental costs) were calculated
as the difference between the total costs of RDTs and anti-
malarials under the different RDT scenarios and total anti-
malarial costs if clinical diagnosis was used. The
incremental costs per malaria positive case treated (ICER)
has been calculated as incremental costs divided by
number of malaria positive cases treated for a given sce-
nario.
Sensitivity analyses
The initial set of assumptions, as described in the method-
ology above, is referred to as the 'base case' in the results
section. One-way and multi-way sensitivity analyses were
performed to assess whether the results are sensitive to
changes in:
• The price of RDTs: the lowest 2004 cost of quality-
assured rapid diagnostic tests, which was US$ 0.65 (e.g.
Paracheck®, Orchid Biomedical, India) was used;
• The price of ACTs: Prices of ACTs lower than the ones in
the base case scenario have been considered for sensitivity
analyses. The preferential price of artemether-lumefan-
trine to the WHO has been reduced to $1.40 per adult
treatment course plus a 3% fee levied by WHO to cover
shipping costs. This provided the basis for the sensitivity
analyses using $1.44 per adult treatment. The interna-
tional median price per tablet of SP USD 0.0257 [25] and
of artesunate costing $0.077 per tablet were also consid-
ered; and
• The age distribution of febrile patients: Three alternative
age distributions were explored in the sensitivity analysis
(see Table 3), increasing the proportion of children in Age
Breakdown 1 and 2, and increasing the adult population
in Age Breakdown 3. These reflect populations with
higher birth rates and those dominated by adult migrant
workers, respectively.
Table 2: Unit prices for antimalarials
Age Group Price per treatment 
course (AS+SP)
Number of tablets 
for full treatment 
course
Age (Weight) Group Price per treatment 
course (AL)
Number of AL 
tablets for full 
treatment course
1–6 years $0.49 3 AS + 1 SP 10–14 kg
(1–5 years)
$0.90 6
7–13 years $0.98 6 AS + 2 SP 15–24 kg
(6–8 years)
$1.40 12
14+ years $1.77 12 AS + 3 SP 25–34 kg
(9–12 years)
$1.90 18
35+kg
(13+ years)
$2.40 24
Table 3: Age breakdown for base case and for three sensitivity analyses
Artesunate plus SP Artemether – lumefantrine
Age (years) 1 – 6 7 – 13 14+ 1 – 5 6 – 8 9 – 12 13+
Base case 28.3% 15.3% 56.4% 23.6% 9.1 8.7 58.6
Age breakdown 1 50% 15% 35% 45% 9% 9% 37%
Age breakdown 2 40% 20% 40% 35% 11.5% 11.5% 42%
Age breakdown 3 10% 5% 85% 8% 2% 2% 88%Page 4 of 14
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each variable are summarised in Table 4.
Results
Total costs and cost savings associated with the use of 
RDTs
Figure 1 shows that the total costs of antimalarials and
RDTs for treating all malaria patients in 2002 in the two
study districts. Using clinical diagnosis, this would be
$42,484 when treating them with AS+SP and $63,048 for
AL. The introduction of definitive diagnosis (using RDTs)
could either result in cost savings or additional costs,
depending on the proportion of febrile patients con-
firmed to have malaria. For the scenario where 25% of
febrile cases are RDT positive, use of definitive diagnosis
before treating patients would result in a cost saving of up
to $1,485 and $16,908, when malaria patients are treated
with AS+SP and AL, respectively, provided that health
workers do not give antimalarials to patients with a nega-
tive RDT. Thus the more expensive the antimalarial being
used, the greater the need for restricting antimalarials to
confirmed malaria cases and the higher the cost savings
that will be realised through effective implementation of
definitive diagnosis.
Incremental costs or cost savings associated with the use of 
RDTs
Figure 2 shows the incremental costs (or cost savings) for
antimalarials and diagnosis under the different scenarios.
For the relatively cheaper ACT (AS+SP), only when 29%
or less of all suspected malaria cases test positive for
malaria will the use of RDTs in all clinically diagnosed
malaria cases result in cost savings, when compared to all
patients being treated with AS+SP on the basis of clinical
diagnosis. This percentage increases from 29% to 41.5%
when use of RDTs is restricted to only those older than six
years of age, and malaria positive patients are treated with
AS+SP. For a relatively more expensive ACT (e.g. arte-
mether-lumefantrine in 2004), as long as fewer than 52%
of tested cases are found to be positive, the use of RDTs in
all suspected malaria cases will result in lower treatment
costs (cost savings) compared to when patients are treated
on the basis of clinical diagnosis; this cut-off shifts from
52% to 74% if use of RDTs is limited to patients who are
over six years of age. This strategy results in lower addi-
tional costs or higher cost savings compared to when
RDTs are used in all suspected malaria cases, for both
AS+SP and artemether-lumefantrine. However, in terms
of cost, there are greater gains in restricting use of RDTs in
patients over six years of age, when treating with a less
expensive ACT (e.g. AS+SP). This is expected since the
price of one RDT ($0.95) is nearly twice as high as the cost
of one dose of AS+SP for a patient younger than or equal
to six years ($0.49), but similar to the cost of an AL treat-
ment course for this age group ($0.90). Hence, treating all
patients younger than or equal to six years with AS+SP on
a clinical basis makes more economic sense than using an
expensive RDT to test this age group.
Cost-effectiveness of RDTs: incremental cost of per 
malaria patient treated
Figure 3 presents results on the incremental costs per
malaria positive patient treated. Incremental costs have been
calculated using total cost of RDTs and antimalarials
divided by the number of malaria cases for the different
scenarios. Findings reported are based on the assumption
that health workers adhere to test results and do not give
antimalarials to patients with a negative RDT. Results in
Figure 3 again show a cost saving (of $0.19 per patient
treated) if malaria is present in under 29% of patients and
that even when 75% of cases are malaria positive, the
incremental cost per malaria positive patient treated is less
than US$ 1, when AS+SP is used for treating malaria
patients.
When patients are treated using artemether-lumefantrine,
there are cost savings per malaria positive patient treated of up
to $2.12 (in the 25% scenario) as long as 52%, or less, of
the suspected cases are RDT test positive. Beyond the 52%
cut-off point, additional costs are incurred with an incre-
mental cost per malaria positive patient treated of up to $0.85
(when 95% of tested cases are found positive and treated
with artemether-lumefantrine). According to the guide-
line provided by the Ad Hoc Committee on Health
Research relating to Future Interventions Options, an
intervention is considered to be "highly attractive" (hence
'cost-effective') in low income countries if it costs less than
$25 per disability-adjusted life year (DALY) averted and
any intervention that costs less than $150 per DALY
averted should be considered "attractive" [26]. Although
Table 4: Values of the variables considered for the sensitivity analyses
Price of SP (per tablet) Price of AS (per tablet) Price of AL (per adult dose) Price of RDTs Age breakdown
Base case $ 0.19 $ 0.10 $ 2.40 $ 0.95 base case
Multi-way 1 $ 0.0257 $ 0.077 $ 1.44 $ 0.65 1
Multi-way 2 $ 0.19 $ 0.10 $ 2.40 $ 0.95 3
Multi-way 3 $ 0.19 $ 0.10 $ 2.40 $ 0.65 3
Multi-way 4 $ 0.0257 $ 0.077 $ 1.44 $ 0.65 base casePage 5 of 14
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patients treated" and not DALYs, this guideline could be
helpful in considering whether an incremental cost per
malaria positive person treated of less than $1 should be
regarded as being highly cost-effective.
Sensitivity analyses
Findings from the one-way sensitivity analysis on varia-
tion in the age distribution show that the higher the per-
centage of adults among the suspected malaria cases (age
breakdown 3), the lower the additional costs and the
higher the costs savings (particularly with a relatively
more expensive ACT like AL) associated with use of RDTs
(Figure 4, quadrant 4), and vice versa. This finding is not
surprising since the price of the ACTs for children is signif-
icantly lower than the price of the adult dose, and yet the
price of the RDT remains constant for all age groups.
Results in Figure 5 show how changes in the age distribu-
tion of patients with clinically suspected malaria have an
impact on the decision on restricting their use to only
those who are over six years of age. The higher the propor-
tion of young children among those with suspected
malaria, the more it makes economic sense to restrict the
use of RDTs to those over the age of six years. The more
expensive the unit price of the antimalarial for the one to
six years age group, relative to the unit price of RDTs, the
lower the cost savings associated with restricting RDTs to
patients over six years of age (Figure 5).
Results of the one-way sensitivity analysis on the RDT
price variable show that as expected, the lower the unit
price of a rapid diagnostic test the more cost-effective it is
to use definitive diagnosis (using RDTs) as the basis for
ACT treatment, regardless of the price of the antimalarial
being used. With a reduction in the unit price of RDTs
from $0.95 to $0.50, limiting the use of RDTs in patients
older than six years would result in significantly less eco-
nomic gains (when patients are treated with AS+SP) and
some economic losses in areas of low to moderate inten-
sity malaria transmission (where 50% or less of fever cases
are malaria positive). The same applies when patients are
treated with AL (quadrant 6, Figure 6). In other words, the
cheaper the RDT the less the need is to restrict to older age
groups.
Similarly, results of the one-way sensitivity analysis on the
ACT price variable show, as expected, that the use of RDTs
will become less cost-effective as the antimalarials become
less expensive. This explains why, at least from an eco-
nomic perspective, RDTs have not been widely used when
cheaper antimalarials, such as chloroquine or sulfadox-
ine-pyrimethamine monotherapy, were being used in
areas of moderate to high intensity malaria transmission.
This may also be the "in-country" scenario with the imple-
mentation of a global subsidy to reduce the price of ACTs
to that of chloroquine [27].
Total cost of antimalarials and RDTs: comparing clinical and definitive diagnosisFigure 1
Total cost of antimalarials and RDTs: comparing clinical and definitive diagnosis.
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presented in Figure 7. In these analyses the prices of anti-
malarials, prices of RDTs and age distribution were varied
to assess the effect of simultaneous changes in these vari-
ables on the earlier findings on cost-effectiveness of RDTs.
Figure 7 shows that, as expected, multi-way 1 (high prices
of ACTs and RDTs and children younger than or equal to
six years of age taking up the highest proportion) is the
context in which routine use of RDTs is least cost saving
(for both AS+SP and artemether-lumefantrine) (quadrant
1, Figure 7). Results of multi-way 2 sensitivity analysis
show the impact of changing age distribution alone (with-
out changing the prices of ACTs and RDTs). There is a
decline in incremental cost per patient treated, from $0.82
to $0.71 and from $0.61 to $0.49 for AS+SP and arte-
mether-lumefantrine respectively, purely as a result of
increasing the proportion of adults in the population with
clinically diagnosed malaria.
Results of multi-way 3 sensitivity analysis (quadrant 3,
Figure 7) show the impact of changing the price of RDTs
and age distribution (without changing prices of ACTs).
Changes in costs are mainly due to the variations in RDT
prices and the proportions of adults treated. As expected,
the bigger the proportion of the suspected cases that are
adults, the greater the cost savings. Variation in the prices
of RDTs and antimalarials shifts the cut-off points at
which definitive diagnosis results in cost savings.
Discussion
With improvements in malaria control and relatively
higher costs of antimalarial treatment, there is increased
opportunity for cost savings through the introduction of
rapid diagnostic tests in facilities and/or communities
where microscopic confirmation of malaria diagnosis is
not reliably available [28]. Amexo and others suggest that
it is unethical to continue with high levels of malaria mis-
diagnosis in light of the introduction of expensive antima-
larials and availability of cost-effective methods of
diagnosing malaria (such as RDTs) [7]. This argument in
favour of limiting antimalarial use to confirmed cases is
strengthened by considering the enormous effect of drug
pressure on antimalarial resistance and the potential for
adverse reactions. This study shows that the introduction
of RDTs is likely to be cost saving when a relatively more
expensive ACT is used for treatment, provided no more
than 52% of those patients clinically diagnosed to have
malaria are found to be parasitaemic. This result holds
Incremental costs (or cost savings) associated with use of RDTs when malaria is confirmed in varying proportions of patients for two ACTs (artesunate plus sulfadoxine-pyrimethamine and artemether-lumefantr ne); excluding 'other recurrent costs'Figure 2
Incremental costs (or cost savings) associated with use of RDTs when malaria is confirmed in varying propor-
tions of patients for two ACTs (artesunate plus sulfadoxine-pyrimethamine and artemether-lumefantrine); 
excluding 'other recurrent costs'.
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the current preferential price to WHO for AL) are used, but
the higher the price of the ACT, the greater the cost savings
from introducing definitive diagnosis and the higher the
cut-off point at which RDTs become cost-saving. Many
countries in Africa have well below 60% of clinically diag-
nosed malaria patients being confirmed on RDT or micro-
scopy. A study in Uganda found that only 57% of those
clinically diagnosed as having malaria were actually para-
sitaemic [29]. From several studies undertaken separately
in 15 countries, Amexo and others (2004) report that on
average there is a 61% overestimation of malaria cases
when clinical diagnosis is used [7].
As malaria control improves as a consequence of wide-
spread use of insecticide treated bednets [30], indoor
residual spraying [23] and or ACT use [16-18,31], the pro-
portion of clinical malaria (fever) cases that would be
definitively diagnosed as malaria will decrease. Conse-
quently the introduction of definitive diagnosis with
RDTs at the same time as the introduction of ACT would
become increasingly cost saving, because there would be
fewer suspected cases to test and even fewer cases to treat.
Findings from our study show that the introduction of
definitive diagnosis (using RDTs) is cost-saving even
when we only consider a narrow perspective of costs
related to malaria treatment (i.e. costs of RDTs and anti-
malarials).
While the use of RDTs in all suspected cases has been
shown to be cost-saving in some instances, our findings
also show that targeting RDTs at the group older than six
years and treating all children less than six years on the
basis of clinical diagnosis is even more cost-saving. In
semi-immune populations, young children carry the larg-
est malaria disease burden and many healthcare providers
would find it harder to deny antimalarials to those who
test negative in this age-group.
Findings from the analyses show that results are sensitive
to the effects of changes in age distribution of the sympto-
matic population, and price of ACTs and price of RDTs.
Increasing proportions of older patients result in
increased cost savings with RDT introduction (due to
lower costs of antimalarials for children, and fixed cost of
RDTs). As the prices of antimalarial treatment increase,
Incremental costs of using RDTs per malaria positive patient treated (base case): based on total costs of RDT and antimalarials (art suna e plu  ulfadoxine-pyrim thamine and art me her-lumefantrine) wh n all suspec ed malaria cases are testedFigure 3
Incremental costs of using RDTs per malaria positive patient treated (base case): based on total costs of RDT 
and antimalarials (artesunate plus sulfadoxine-pyrimethamine and artemether-lumefantrine) when all sus-
pected malaria cases are tested.
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Impact of changes in age distribution of suspected malaria cases on incremental cost per malaria patient treatedFigure 4
Impact of changes in age distribution of suspected malaria cases on incremental cost per malaria patient 
treated.
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Impact of changes in age distribution of suspected malaria cases on incremental costs of RDTs + antimalarials (excluding other recurrent costs)Fig r  5
Impact of changes in age distribution of suspected malaria cases on incremental costs of RDTs + antimalarials 
(excluding other recurrent costs).
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Age breakdown 2 for ASSP 40%; 20%; 40% and for AL 35%; 11.5%; 11.5%; 42%
Age breakdown 3 for ASSP 10%; 5%; 85% and for AL 5%; 4.5%; 4.5%; 86%
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Impact of changes in price of RDTs on Incremental cost per patient treated and total incremental costsFigure 6
Impact of changes in price of RDTs on Incremental cost per patient treated and total incremental costs.
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However, when less expensive ACTs are introduced, such
as for the current WHO preferential price of $1.44 per
adult treatment, the RDT price to the healthcare provider
should be $0.65 or lower for RDTs to be clearly cost saving
in populations with between 30% and 52% of clinically
diagnosed malaria cases being confirmed malaria cases.
The analysis of the potential benefits of introducing RDTs
in combination with ACTs is more complex if the majority
of malaria treatment is self-administered or sought in the
private and informal sectors. Furthermore, for treatment
of fever cases testing negative for malaria, some healthcare
providers may still use antimalarials and there may be an
increased risk of irrational use of other drugs, particularly
antibiotics. This necessitates integrated training and
supervision of health workers in rational drug use for the
treatment of non-malaria fever cases and enhanced drug
utilisation monitoring, particularly at the time of RDT
introduction. Village health volunteers in Laos were
found to only require minimal training (one hour) to sus-
tain reliable use of RDTs over a 10 month period [32]. In
contrast, a study conducted in Zambia, where specific
training and supervision of healthcare providers was not
provided, significant underutilization of RDTs or the
inappropriate prescription of antimalarials when patients
test negative have been documented [5]. However, a study
in Tanzania concluded that use of rapid diagnostic tests,
Multi-way sensitivity analyses: Incremental cost per malaria patient treatedFigure 7
Multi-way sensitivity analyses: Incremental cost per malaria patient treated.
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tests should lead to alternative diagnoses being consid-
ered", did not lead to lead to any reduction in over treat-
ment for malaria [6].
Although the additional benefits of avoiding the use of
ACTs to patients in whom the malaria diagnosis is nega-
tive could not be included in this study, these are likely to
be substantial. Assuming education interventions succeed
in ensuring that test results are accepted by healthcare pro-
viders, patients and caregivers, excluding malaria would
facilitate earlier diagnosis and treatment of the actual
cause of the disease for those who are malaria test nega-
tive, and would minimise the treatment seeking costs
related with repeat visits and the productivity losses asso-
ciated with prolonged illness. It has been argued that the
effects of malaria misdiagnosis fall most heavily on the
poor and vulnerable who are least able to withstand pro-
longed ill-health and the associated missed opportunities
for earning an income [9]. In addition, the use of defini-
tive diagnosis would provide more reliable data on
malaria cases, hence allowing for accurate forecasting of
required antimalarials for planning and budgeting and
better monitoring of the effectiveness of malaria control
interventions. Also, drug pressure, and consequently, the
rate of spread of antimalarial resistance could be
decreased.
The findings of this study show that the introduction of
RDTs is likely to be cost saving when ACTs are imple-
mented, particularly in areas of low to moderate intensity
malaria transmission. The finding that drug cost-savings
are higher in low transmission areas was also reported by
Goodman and others [1]. This is because in low transmis-
sion areas, a higher proportion of malaria cases are adults
who require a higher antimalarial dose (and for whom
antimalarials thus cost more). This effect results in higher
malaria prevalence cut-off point at which RDTs are cost
effective. Similar findings are reported by Rolland and
others where the cost-effectiveness of RDTs is studied in
the context of malaria epidemics. They report that RDTs
would be cost-effective at a malaria prevalence of up to
45% when AS+AQ is used for treatment and up to 68%
when artemether-lumefantrine is used [33].
It is also important to note that clinical diagnosis may fail
to pick up some patients who actually have malaria. Lux-
emburger and others found that none of the malaria
symptoms alone or in combination proved to be a reliable
predictor of malaria, and at best clinical diagnosis would
result in prescription of antimalarials in 29% of the non-
malaria febrile illnesses and 49% of the true malaria cases
(suggesting that 51% of the infections would go untreated
initially) [7]. It is important to note that RDTs are unlikely
to be used if malaria is not clinically suspected and so will
not address the problem of false negatives arising from
clinical diagnosis. Furthermore, the extent to which RDTs
are cost-effective depends on their accuracy in diagnosing
malaria. Studies have found varying levels of sensitivity
and specificity of the different RDT products on the mar-
ket. Swarthout and others (2007) recently reported 52%
specificity of Paracheck-Pf in Democratic Republic of
Congo and noted that as many as 92% of children were
still false positive at day 28 following treatment with arte-
mether-lumefantrine [34]. Similar results are reported by
Kleinschmidt and others (2007) for Equatorial Guinea
[35].
Conclusion
Rapid, accurate and accessible detection of malaria para-
sites has an important role in addressing the problem of
malaria over-diagnosis and inappropriate use of antima-
larial drugs. RDTs offer the potential to provide accurate
diagnosis to all populations at risk, particularly those una-
ble to access good quality microscopy services. In the con-
text of expensive antimalarial drugs (such as ACTs),
deploying RDTs can be cost-saving or cost-effective
depending on the price of RDTs and ACTs, the age distri-
bution of and the prevalence of malaria parasites among
clinically diagnosed malaria patients. This result holds
true only if health workers prescribe and or dispense anti-
malarials to only the patients that are found to be malaria
test positive.
However, in most malaria endemic countries, access to
preventive, diagnostic and curative services remains lim-
ited due to a range of access constraints, including health
service costs. Care should be taken to ensure that the costs
of new and apparently cost-saving interventions, such as
RDTs, are not borne by households. In this era where the
use of ACTs is being globally encouraged and financed,
strategies such as the concurrent use of ACTs and RDTs
should be equally encouraged and financially supported
unless the majority of clinically diagnosed malaria cases
are parasitaemic.
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